Previous close | 216.57 |
Open | 216.74 |
Bid | 212.91 x 800 |
Ask | 218.33 x 800 |
Day's range | 215.64 - 218.67 |
52-week range | 179.59 - 234.09 |
Volume | |
Avg. volume | 747,793 |
Market cap | 18.372B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 50.45 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.32%) |
Ex-dividend date | 26 Feb 2024 |
1y target est | N/A |
Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.